EIKN (NASDAQ:EIKN) Given Underperform Rating at Wedbush

Wedbush reissued their underperform rating on shares of EIKN (NASDAQ:EIKN) in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a $7.00 price objective on the stock.

EIKN has been the topic of a number of other reports. Mizuho assumed coverage on shares of EIKN in a research note on Monday, March 2nd. They set an “outperform” rating and a $26.00 price target on the stock. Bank of America assumed coverage on shares of EIKN in a research note on Monday, March 2nd. They issued a “buy” rating and a $34.00 price objective for the company. Cantor Fitzgerald began coverage on shares of EIKN in a report on Monday, March 2nd. They set an “overweight” rating on the stock. Wall Street Zen upgraded EIKN from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. assumed coverage on EIKN in a report on Monday, March 2nd. They issued an “overweight” rating and a $29.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, EIKN currently has an average rating of “Moderate Buy” and a consensus price target of $25.60.

EIKN Price Performance

Shares of NASDAQ:EIKN opened at $10.58 on Tuesday. EIKN has a twelve month low of $9.46 and a twelve month high of $17.40.

About EIKN

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.